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Rating: Buy, with High Risk 
Company Name:    Galectin Therapeutics, Inc. 
Date:    5/13/2016 
Fiscal year ends:    3/15/2016 
Current price:    $1.44 
52 week high:    $4.11 
52 week low:    $1.08 
Market Cap:    $42.1 Million 
Enterprise Value:    $29.9 Million 
Total Debt:    N/A 
Cash:    $21.3 Million 
Net Debt/Enterprise Value:    N/A 
Dividend Yield:    N/A 
Diluted Shares Outstanding:    25.9 Million 
Current P/E:    N/A 
2017 EPS:    -$0.69* 
2016 EPS:    -$0.69* 
2015 EPS:    -$0.88 
2014 EPS:    -$0.78 
2013 EPS:    -$1.30 
2012 EPS:    -$0.72 
*Consensus estimates as of the time of this writing. 
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Galectin Therapeutics, Inc. (NASDAQ: GALT) is a clinical-stage biopharmaceutical company 
headquartered in Atlanta, GA. The company focuses on drug discovery and development; its 
main goal is to develop new therapies for fibrotic disease and cancer. Based on historical 
averages, recent statements from the management team, and our own estimations, our uniquely 
developed discounted net present value (NPV) model, together with Monte Carlo simulations, 
give a probable net present value of $2.89 per share, which is 100% higher than the current price 
of $1.44. However, the current price is sitting at the 75th percentile of the price distribution 
obtained from Monte Carlo simulations, meaning it has a 75 percent chance of falling and a 25 
percent chance of rising. As a result, we rate GALT as a BUY, but with high risk.    
Catalysts and Risks 
 
 If at least one drug hits the market, the potential is huge; in particular, because there are 
no current therapies for treatment of liver fibrosis, if approved, GR-MD-02 will be the 
only go-to drug in the market.    
 Since GALT is a pre-profit biotechnology company, it has not been able to generate any 
revenue, and hence has incurred net losses in each year of operation since 2000. 
 The current, “burn rate,” of the company, calculated by summing the research and 
development (R&D) and the selling, general, and administrative (SG&A) expenses, is 
relatively high compared to the amount of cash the company has. As a result, it is 
estimated that there is only sufficient cash to fund operations through the first quarter of 
2017.  
 There is a high chance that none of drugs in the company’s pipeline will hit the market. 
 The company might be unable to commercialize its products even if they receive 
regulatory approvals.  
Company Description and Historical Performance 
Company Description 
 
Galectin Therapeutics, Inc. (NASDAQ: GALT) is a clinical stage biopharmaceutical company 
focused on drug discovery and development. The company’s drug candidates aim at targeting 
galectin proteins, which are key mediators of pathologic functions. It has been shown that there 
is a large number of galectin proteins implicated in many important diseases, such as 
inflammatory diseases, scarring of organs, and numerous cancers. GALT’s strategy is to focus on 
serious diseases for which there are limited treatment options available.  





Galectin Therapeutics, Inc. was incorporated in Massachusetts in July 2000 as Pro-
Pharmaceuticals, Inc. On April 25, 2001, the company completed a stock exchange agreement 
with DTR-Med Pharma Corp. (“DTR”), whereby DTR purchased all of the company’s 
outstanding common shares. On June 7, 2001, there was a merger between the two companies; 
the new company was renamed “Galectin Therapeutics Inc.” In October 2012, GALT moved its 
headquarters to Atlanta, GA. The company went public in the same year, listed under the 
NASDAQ stock exchange symbol GALT. GALT has minimal exposure to ETFs, being included 
in only 2 ETFs, IWC and ITOT1.  
Product Pipeline 
 
GALT is pursuing therapies for indications where galectin proteins have a demonstrated role in 
the pathogenesis of a particular disease. The company is currently engaging in several drug 
development programs. Ongoing programs, along with their respective stage of development, are 
listed in the following figure: 
  
 
  Figure 1: GALT Pipeline. Retrieved from the company’s website. 
 
                                                            
1 https://www.etfchannel.com/symbol/galt/ 




GR-MD-02, a new chemical entity in development, has shown some positive results in 
preclinical and early clinical studies in treatment of fibrosis and in cancer therapy. After 
chemical processing, GR-MD-02 – a proprietary, patented compound derived from natural and 
plant-based starting materials – has the ability to bind and inhibit galectin-3 proteins. The other 
new chemical entity, GM-CT-01, is also a proprietary and patented compound that is currently in 
the pipeline.  
 
Besides conducting in-house research at SBH laboratories in Massachusetts, the company also 
contracts with independent laboratories and other facilities to conduct research, assist in 
designing clinical trial protocols, and monitor clinical trials. GALT, however, holds all the 




In the past five years, GALT’s stock has been in the range of $1.08 - $16.86. The stock reached 
its peak in early 2014. It plummeted more than 55% on July 29, 2014, from $14.54 to $6.41, due 
to an unfavorable report from an early-stage trial of GR-MD-02 for treatment of a fatty liver 
disease. This reflects the inherent risk in pre-profit biotechnology companies2. The stock then 
went on a downward trend, possibly due to a securities fraud class action lawsuit that accused 
Galectin and some of its officers and directors for purposely hiring a penny-stock promotions 
firm to conduct an illegal stock promotion campaign on behalf of Galectin3. Finally, as can be 
seen from Figure 2, GALT’s stock price does not show any correlation with either the NASDAQ 
(CMMP) Index or the Standard & Poor’s (S&P) Index.  
 
Due to some positive results from recent trials, we believe that there are some catalysts that 
signal potential future earnings growth for GALT. As a result, the stock may be poised to 
appreciate in value significantly. Our hypothesis is supported by financial analysts: 3 out of 3 
analysts covering GALT rate it a buy, with an average target price of $7.00 (see Figure 3, 




                                                            
2 https://www.thestreet.com/story/12825050/1/why-galectin-therapeutics-galt-stock-is-plummeting-today.html 
3 http://www.classactionsnews.com/investments/galectin-therapeutics-galt-securities-fraud-class-action-lawsuit 





Figure 2: 5-year price chart of GALT’s stock, the CCMP Index, and the S&P Index. Source: 
Bloomberg terminal (function <GP>).   
 
 
Figure 3: Analyst Recommendations for GALT.  Source: Bloomberg Terminal (function 
<ANR>) 




Model of the Company  
General Overview 
 
Since GALT is a pre-profit biotechnology company, we developed a proprietary discounted net 
present value (NPV) model to estimate its stock price. As shown in Figure 1, GALT has many 
drugs in its pipeline, and they are in various stages of development. However, because of the low 
probability of drug success (only 1 out of 5,000-10,000 molecules studied in the discovery stage 
makes it to the market as an approved drug4), we only used GALT’s most developed drug, GR-
MD-02, for treatment of non-alcoholic steatohepatitis (NASH) with cirrhosis, to project the 
company’s future earnings. This conservative approach has one drug in the pipeline projected to 
move forward and the company’s projected expenses assume none of the other drugs get 
approved, thus understating potential earnings and overstating expenses.  
Balance Sheet and Income Statement Trends 
 
In the balance sheet, a line-item that stands out is the tremendous increase of about $20 million 
in cash and cash equivalents from 2013 to 2014. This is due to the company issuing new shares 
during the time the stock price was at its peak (Figure 4). Other than that, all other line items, 
especially the company’s liabilities, in the balance sheet stay relatively constant over the past 5 
years, signaling good management. In addition, the company has no long-term debt, a good sign 
for investors. 
 
Figure 4: GALT’s current shares outstanding from 2011 to 2016.  Source: Bloomberg 
Terminal (function <GP>) 
                                                            
4 Keegan, K. D. (2008). Biotechnology valuation: An introductory guide. Chichester, England: John Wiley & Sons. P. 
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As a pre-profit biotechnology company, the company is not generating any significant revenues, 
which is reflected in the income statement. We expect this to continue for a few more years until 
any drug in the pipeline hits the market. In addition, we can see a clear increasing trend in the 
amount of capital spent on research and development reflecting the capital intensive drug 
approval process. From 2010 to the first quarter of 2016, the operating expenses have grown 
consistently from about $1 million to more than $17 million. For a biotechnology company, this 
is reasonable because the further a drug advances to the next stage of development, the more 
capital it is going to require to fund additional research. Since it costs the most to conduct Phase 
2 and Phase 3 trials, usually $10-$15 million and $30-$65 million respectively5, we expect this 
trend to continue in the near future.     
 
One important point to notice is that at the current burn rate, which is calculated by summing the 
R&D and SG&A expenses, the cash and cash equivalents available will not be sufficient to cover 
the company’s operations after the first quarter of 2017. As a result, this presents the inherent 
risk that the company will issue additional shares to the market to raise capital or seek other 
sources of capital. 
Model of FDA Drug Approval Process 
 
The discovery and development process for new drugs to pass the regulatory authorities into the 
marketplace can be divided into five main stages: drug discovery; preclinical development; early 
clinical phase incorporating phase 1 and 2 studies; phase 3 trials; and phase 4 trials (or post-
marketing surveillance studies). Since most of GALT’s drugs have passed the preclinical 
development stage, we only focus on the four phases that come after it. The phase success rate 
for each phase, defined as the probability that a drug will obtain marketing approval from its 
current phase, is outlined in Table 1.  
 
Table 1-The phase success rate at various phases 
Phase 1 15% 
Phase 2 25% 
Phase 3 60% 
Phase 4 90% 
Source: Keegan, K. D. (2008). Biotechnology valuation: An introductory guide. 
Chichester, England: John Wiley & Sons. P. 40 
As previously mentioned, we only projected potential revenues from GALT’s most advanced 
drug, GR-MD-02, which is a lead candidate for treatment of fibrotic liver disease associated with 
NASH, particularly for patients with cirrhosis. Since the drug is in phase 2, its expected 
                                                            
5 Keegan, K. D. (2008). Biotechnology valuation: An introductory guide. Chichester, England: John Wiley & Sons. P. 
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probability of success is 25%. Because the phase success rate obtained in Table 1 is just the 
average value over many different drugs, instead of using a point estimate for the probability that 
GR-MD-02 is going to be a success, we used a probability distribution, with the mean of the 
distribution at 25%. Since our probability distribution ranges from 0 to 1(or 0% to 100%), a beta 
distribution is the most appropriate model to use. The probability density function of a beta 





 𝑓𝑜𝑟 0 < 𝑥 < 1,
0 , 𝑓𝑜𝑟 𝑥 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒
 




Solving for the mean and variance, we obtain: 




𝑉𝑎𝑟(𝑋) = 𝜎2 =
𝛼𝛽
(𝛼 + 𝛽)2(𝛼 + 𝛽 + 1)
   
 With the expected probability of success at 25% and the variance at 10%, we can solve 







) 𝜇2 = 4.4375 
𝛽 = 𝛼 (
1
𝜇
− 1) = 13.3125 
These values of α and β yield the following probability density function: 





Figure 5: The distribution of probability of success for GR-MD-02  
We then create a uniform distribution from 0 to 1 and a binary cell that only takes a value of their 
0 or 1. Finally, we compare this random variable to the probability of success variable: If it is 
greater, the binary cell takes the value 1 (meaning the drug is going to be a success); on the other 
hand, if it is smaller, the binary cell takes the value 0 (meaning the drug will not be approved). 
We will then multiply the projected revenue with this binary cell to calculate the expected 
revenue for every scenario. A snapshot of the model in Excel is given in Table 2. 
Table 2: FDA Drug Approval Process Model 
    alpha beta 
 Probability of drug success  25% 4.4375 13.3125 
Uniform (0,1) R.V. generation: 0 
 
  
Is Uniform R.V. generated greater than probability 
of success? (1=Yes, 0=No). Multiply this by profits 1  
  
    
 
Lastly, we must also consider is the timeline of the FDA approval process. Assuming success, 
the drug will fit into the following timeline: 
   
 
 




  Table 3: Timeline for FDA approval process 
Year Stage 
2016 Phase 2 
2017 Phase 2 results 
2018 Initiate Phase 3 
2019 Phase 3 results 





Having determined the probability of success for the drug, we will then project revenues for the 
next 10 years. The steps that must be taken to model revenue growth are outlined below: 
1. Model the U.S. population 
First, we assume that GALT only operates in the United States. This is a reasonable 
assumption because it is still a young company. As a result, the potential market for 
GALT’s drugs is U.S. residents. To model the population, we calculate the population 
growth in the past 10 years, which gives an average of 0.79% and a standard deviation of 
0.15%. We then use these parameters to assign a normal distribution to future population 
growth rate.   
2. Model the proportion of U.S. population with NASH 
According to the National Institute of Diabetes and Digestive and Kidney Diseases, 2 to 5 
percent of Americans are affected by NASH. In addition, this number is increasing 
because of the higher obesity rate6. As a result, the percentage of U.S. population with 
NASH is assumed to have a uniform distribution from 2 to 5 percent in the first year, 
with an increment of 0.5% for every year after that. 
3. Model the proportion of U.S. population with NASH who might develop cirrhosis 
It is estimated that 8 to 26 percent of people with NASH might develop cirrhosis7. As a 
result, a uniform distribution from 8 to 26 percent is used for every projected year in the 
model. 
4. Model the drug price 
According to GALT’s 2015 10-K, there are 1-2 million Americans who have cirrhosis, 
and about 50,000 of those die every year. Unfortunately, the only treatment available is to 
perform liver transplantation at a cost of approximately $350,000 per transplant. Hence, 
if GR-MD-02 hits the market, it would not be unreasonable to assume the price of such 
drug to be in the range of $1,000 - $1,500, as Gilead Sciences’ hepatitis C drug was 









priced at $1,125 per pill8. We even believe that the price assumed is somewhat 
conservative compared to the cost of performing liver transplantation. In addition, we 
assume a market penetration of 5% for the first year with a 1% growth for every year 
afterwards. Since as of now there are no competing drugs in the market, this is a realistic 
assumption. All of these values are modeled using a normal distribution.  
Expense Projection 
 
As mentioned earlier, the later stages of the FDA approval process cost much more than earlier 
stages. As a result, in 2016 and 2017, when the drug is in phase 2, we project R&D expense 
growth rate at 30%. In 2018 and 2019, when the drug is in phase 3, this number grows to 50%. 
For every year afterwards, the R&D expense growth rate is assumed to drop down to 5% to 
account for post marketing surveillance trials.  
 
On the other hand, general and administrative expense growth rate is assumed to be constant at 
1.6%, its historical value. In addition, after the drug hits the market, we introduce a new sales 
and marketing expense, which is projected to consume 25% of revenue. Finally, for every year 
the company makes a profit, the tax rate as a percentage of EBITDA is assumed to be 30%.  
Similar to the revenue projection, all of these expenses are assumed to be normally distributed in 
our Monte Carlo simulation.  
Net Present Value (NPV) Model 
 
For every projected year, subtracting total expenses from expected revenue gives us expected net 




(1 + 𝐷𝑖𝑠𝑐𝑜𝑢𝑛𝑡 𝑅𝑎𝑡𝑒)𝑘
,  
𝑤ℎ𝑒𝑟𝑒 𝑘 𝑟𝑒𝑝𝑟𝑒𝑠𝑒𝑛𝑡𝑠 𝑡ℎ𝑒 𝑛𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝑦𝑒𝑎𝑟𝑠 𝑝𝑎𝑠𝑠𝑒𝑑 𝑠𝑖𝑛𝑐𝑒 2016 
 
For the final year, 2026, its NPV also accounts for all the future NPVs as a terminal value. Using 
a discount rate of 10% and a residual growth rate of 1.5%, the NPV in the final year is calculated 
using the following formula: 
 
𝑁𝑃𝑉 𝑖𝑛 2026 =
(𝑁𝑒𝑡 𝐼𝑛𝑐𝑜𝑚𝑒)




                                                            
8 http://www.uptodate.com/contents/nonalcoholic-fatty-liver-disease-nafld-including-nonalcoholic-
steatohepatitis-nash-beyond-the-basics 






Assuming the drug turns out to be a success, our NPV model gives a NPV/share of $2.89, which 
is 100% higher than the current price. However, as with any drugs in development, there is a 
very high chance that GR-MD-02 is not going to be approved. As can be seen in the price 
distribution, at the current price of $1.44, there is 75% chance that the stock price will fall below 
that and only 25% chance that the stock price will be a home run. However, if the drug hits the 
market, potential return is huge. Since we took a conservative approach in our model, as 
explained in above sections, this means we should expect an even higher return.    
 
Figure 6: Distribution of GALT stock. The current stock price falls in the 75th percentile. The red region 





Since management is able to allocate capital at its own discretion, we performed a compensation 
analysis to determine if management is incentivized to generate returns for shareholders.  
 
According to GALT’s 2014 proxy statement, executive compensation comprises of 3 main 
components: 
1. Base salary 




2. Annual Performance bonuses 
3. Long-term compensation in the form of equity-based awards 
Base Salary 
 
Base salary is the only fixed component in the executive compensation program. Named 
Executive Officers (NEO)’s base salaries are reviewed annually, taking into account marketplace 
rates, individual responsibilities, performance, and experience. In 2014, only 2 out of 4 NEOs 
got a base salary raise.  
Table 4: Base salaries for NEOs in 2013 and 2014 
Name    2013 Base Salary      2014 Base Salary   
Peter G. Traber, M.D.    $ 375,000      $ 485,000   
James C. Czirr    $ 240,000      $ 240,000   
Harold H. Shlevin, Ph.D.    $ 200,000      $ 230,000   
Jack W. Callicutt    $ 175,000      $ 175,000   
  
Annual Performance Bonuses  
 
The annual cash bonus is targeted to be up to 20% to 40% of the NEO’s base salary. 50% of each 
NEO’s annual performance bonus is based on the company’s performance objectives for the year 
and the other 50% is based on individual performance objectives. According to the company’s 
DEF 14A form, the overall performance objectives for the company in 2014 are: 
 
 
(1) Establish human proof of concept for GR-MD-02 treatment of non-alcoholic steatohepatitis with advanced 
fibrosis.  
  
  (2) Establish human proof of concept for use of galectin inhibitors in combination with immunotherapy for 
cancer.  
  
  (3) Establish sustainable program for GR-MD-02 manufacturing and controls.  
  
  (4) Establish appropriate quality assurance and quality control oversight and strengthen regulatory support.  
  
  (5) Strengthen and expand pipeline and indications for galectin blocking drugs.  
  
  (6) Strengthen business practices, financial resources, investor communication and strategic partnerships.  
 
The actual amounts of annual performance bonuses awarded to the NEOs in 2014 are included in 
Table 5. 
 
Table 5: Annual performance bonuses in 2014   
Name    Annual Performance Bonus Amount      Awarded Amount As % of Base Salary   
Peter G. Traber, M.D.    $ 213,400        57 %  
James C. Czirr    $ 84,000        35 %  
Harold H. Shlevin, Ph.D.    $ 77,625        33.75 %  
Jack W. Callicutt    $ 38,500        22 %  
 




Long-term Incentive Compensation 
 
The amount of options granted to each NEO is based upon company performance, individual 
performance, and rank in the company. The exercise price of these options is set at the closing 
price of the stock as of the grant date.  
 
Total compensation for all the NEOs is included in Table 6. 
 
Table 6: Executive compensation for the period 2012-2014  
Name and Principal Position    Year      
Salary 
($)      
Bonus 
($) (2)      
Option 
Awards ($) 
(1)      
All Other 
Compensation 
($)     Total ($)   
Peter G. Traber, M.D.      2014       485,000       213,400       1,512,150       41,502 (5)      2,252,052   
Chief Executive Officer & 
President 
     2013       375,000       194,688       —         43,002 (6)     612,690   
     2012       314,946       25,000       713,332       36,021 (7)     1,089,299   
James C. Czirr      2014       240,000       84,000       688,367       75,882 (8)      1,088,249   
Executive Chairman and Director      2013       240,000       120,025       —         77,189 (9)     437,214   
     2012       212,503       —         —         79,689 (10)     292,192   
Harold H. Shlevin, Ph.D.,      2014       230,000       77,625       428,819       35,304 (11)     771,748   
Chief Operating Officer (3)      2013       200,000       59,975       —         32,454 (12)     292,429   
      2012       50,000       25,000       473,381       8,908 (13)     557,289   
Jack W. Callicutt,      2014       175,000       38,500       293,402       38,812 (14)     545,714   
Chief Financial Officer (4)      2013       87,500       39,803       709,542       17,074 (15)     853,919   
      2012       —         —         —         —         —     
 
Even though the parameters that go into the calculation of long-term incentive compensation are 
not clearly aligned with shareholders’ interests, the fact that many of the objectives aim at 
growing the company and that the option awards take a large proportion of each NEO’s 
compensation is a good sign to investors.    
Dividend and Share History 
 
GALT has not declared any dividends since the day it was founded. This is not a surprise given 
the fact that it has not been able to generate any revenues. In addition, as can be seen in Figure 4, 
the company’s outstanding shares have been on an upward trend for the last few years because 
the company prefers equity financing to long-term debt to raise capital. We expect this trend to 










Holders and Insider Trading 
 
 
Figure 7: GALT’s Institutional and Insider Shareholders 
 
Figure 7 (above) is a list of GALT’s shareholders in order of positions in the company. At the 
top of the list is 10x Fund LP, owned by Rod D. Martin, a director, and James Czirr, executive 
chairman and a director. It is reassuring to see many GALT insiders, marked by the “Form 4” 
source title, in this ownership table. It shows that many of these executive officers have their, 
“skin in the game,” and they are incentivized to maximize shareholders’ return.  
 
A snapshot of insider transactions is provided in Figure 8. The dominance of green pentagonal 
shapes, which represents purchases of shares, suggests that the officers believe in the future of 
the company.  





Figure 8: GALT’s Insider Transactions.  
Conclusion 
 
With recent positive results from Phase 2 trials, GR-MD-02, the lead candidate for treatment of 
fibrotic liver disease associated with NASH, is getting closer to being approved. Our discounted 
NPV and Monte Carlo simulation shows us that if the drug hits the market, GALT will have a 
huge upside potential. This, though, comes with a high risk: GALT’s stock is projected to go 
upward in only 25% of the scenarios. However, with a good management team, whose interests 
also align with shareholders’, we believe GALT is positioned to become a winner given the 
risk/reward asymmetry. Thus, we rate GALT as a BUY, with high risk.   
